Kornimate/medical-research-clean huggingface dataset:
linked color imaging to differentiate h. pylori associated gastritis and gastric atrophy

Conditions: Gastritis; Helicobacter Pylori Associated Gastritis; Atrophic Gastritis

Summary: h. pylori infection plays a very important role in gastric carcinogenesis, progressing from chronic gastritis through atrophic gastritis, intestinal metaplasia, dysplasia and finally cancer. it is difficult to diagnose h. pylori related gastritis and gastric atrophy on the basis of endoscopic findings. histology is currently considered to be the gold standard for detecting h. pylori infection. the reliability of detecting h. pylori infection histologically depends on the site, number, and size of gastric biopsy specimens. the blind biopsy sampling of normal appearing mucosa has the risk of missing pathology and sampling errors. most studies conclude that as well as on expertise in staining and visualizing the bacteria. considerable error also occurs in identifying gastric atrophy using blind biopsy sampling, and neither the original nor the revised version of the sydney system reliably identifies more than half the cases in patients with confirmed gastric atrophy.

nbi is the most widely used system among several available image enhanced endoscopy systems. however, this technique has limitations such as dark imaging of distant lesions because of narrow-band illumination. blue laser imaging (bli) was developed to compensate for these inherent limitations of nbi. bli uses narrow-band laser light combined with white light. this combination results in a bright image of the digestive mucosa, enabling the detailed visualization of both the microstructure and the microvasculature. however, bli still is not able to obtain sufficient brightness for distant lesions. the newly developed linked color imaging (lci) system (fujifilm co.) creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of bli technology. this system can obtain bright endoscopic images even at a distant view because lci has more intense white light than the short-wavelength narrow-band laser light. short-wavelength narrow-band laser light enhances the vessels on the mucosal surface and the patterns of the mucosa, which means that bli enables a clearer visualization of microvascular structures than does lci. in contrast, lci enhances differences in hue, in the red region of the spectrum, through digital processing. this makes red areas appear redder and white areas appear whiter. thus, it is easier to recognize a slight difference in color of the mucosa. therefore, lci may facilitate the detection of h. pylori infection and gastric atrophy. further studies are needed to confirm the utility of lci.

Eligibility criteria:
inclusion criteria: * above 18 years old patients * who agree to participate in the study * patients with the indications for gastroduodenoscopy exclusion criteria: * patients, who were receiving nonsteroidal anti-inflammatory drugs, pump inhibitors (ppi) or antibiotics in the last 3 weeks. * severe uncontrolled coagulopathy * prior history of gastric surgery. * pregnancy and lactation
dabigatran study in the early phase of stroke. new neuroimaging markers and biomarkers study (sedman study)

Conditions: Cardioembolic Stroke

Summary: sedman study is a prospective multicenter investigator initiated study (iis). the main idea is to look by genome wide association (arrays that determine more than 1 million polymorphisms) genetic risk factors associated with response to dabigatran. to conduct the study, the goal is to recruit 300 patients with ischemic stroke with cardioembolic etiology treated with dabigatran and 200 treated with acenocoumarol to determine if genetic risk factors are associated with the occurrence of any bleeding or vascular event in a year follow-up.

data will be analyzed through gwas analysis. the results will be analyzed by experienced genotypic bioinformatics: plink, haploview, stata, impute2, snptest, gtool, galaxy management. in addition, the investigators have support of spanish consortium for genetics of stroke (genestroke). the plink software is the main program for the analysis of gwas. using this software we can clean the raw results of genotyping platforms and determine the presence of risk alleles associated with resistance to the study drugs. haploview software will be used for data management and graphics for significance analysis. stata statistical software is a data management and very useful for the creation of q_q plots graphs that assist in the interpretation of genotypic results. gtool, snptest and impute2 are software for data imputation and analysis of imputed data through the information available in the 1000 genomes project.

Eligibility criteria:
inclusion criteria: * patients of both sexes who are ≥ 18 years of age * patients with stroke or tia in last 14 days and a diagnosis of non-valvular atrial fibrillation who initiate treatment with dabigatran or classical acos (acenocoumarol) to prevent stroke or non-cns systemic embolism. * patients with mild/moderate strokes (i.e. strokes less than 2/3 of vascular territory with initial aspects on first ct/mri \> 6 and nihss \<25). * patients who have an overall condition which allow the 12 months' follow-up. exclusion criteria: * patients with an indication of oral anticoagulants for primary prevention or with an indication other than cardioembolic etiology. * patients with contraindications to use anticoagulants. * patients who do not wish to participate in the study and have not signed informed consent. * patients with non-controlled hypertension or hypertensive crisis will be also excluded. * patients with a life expectancy of less than one year. * patients with psychological or social factor which not allow a correct follow-up. * patients with severe/disabling strokes (i.e. more than 2/3 of vascular territory, nihss≥25).

Keywords: stroke oral anticoagulants cardioembolic
primary prophylaxis of gastric variceal bleed

Conditions: Gastric Varices

Summary: the purpose of this study is to study the efficacy of endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration in the prevention of gastric variceal bleeding.


Eligibility criteria:
inclusion criteria: 1. cirrhosis 2. patients with high risk gastric varices (gov2 or igv1) 3. presence of gastrorenal shunt exclusion criteria: 1. acute bleed or past history of bleed from gastric varices 2. previous treatment of gastric varices. 3. non-cirrhotic portal hypertension 4. contraindications to cyanoacrylate injection or brto 5. portal cavernoma 6. hepatorenal syndrome 7. proven malignancy including hepatocellular carcinoma 8. end-stage renal disease under renal replacement therapy; 9. cardiorespiratory failure 10. pregnancy or patients not giving informed consent for endoscopic procedures
smartphone application for the management of gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: the prevalence of gestational diabetes mellitus (gdm) has been progressively increasing. it is important to recognize and treat gdm to minimize the risk of maternal and neonatal complications. multifaceted professional interventions are effective in the management of gdm and mobile healthcare can be an effective approach. the purpose of the current study was to develop and evaluate a model for prevention and management of gdm using mobile healthcare. subjects with no previous history of diabetes, who were diagnosed with gdm during 24-28 weeks of gestation, were randomly divided into a conventional management group and a mobile management group. the conventional mangement group received conventional gdm management and could freely use the mobile healthcare application. the mobile management group received mobile healthcare services including tailored mobile coaching. the effectiveness of the management using the application were evaluated through the result values of the laboratory tests, anthropometric measurement performed during the study period and perinatal outcomes.


Eligibility criteria:
inclusion criteria: * singleton pregnant women diagnosed as gdm at 24 to 28 weeks of gestation were included. exclusion criteria: * patients after 30th week of gestation and patients with pregestational diabetes were excluded from participating in the study. patients who were unable to understand korean, were unfamiliar with mobile phones, who did not have access to a mobile phone, or who were already receiving services from another mobile healthcare agency were also excluded.
effect mechanism of custom-made foot orthoses in patients with chronic low back pain

Conditions: Chronic Low Back Pain; Foot Pronation

Summary: excessive foot pronation has been recognized as being linked to chronic low back pain (clbp). the use of compensating custom-made foot orthoses has not been entirely explored as an effective therapy for clbp objective: to investigate the effects of wearing custom made foot orthoses compared to placebo orthoses in patients with pronated feet and chronic low back pain (clbp).

excessive foot pronation has been recognized as being linked to clbp. foot hyperpronation may cause malalignment of the lower extremity.there is a wide variety of treatments for clbp, and it is suggested that excessive pronation of the foot has been linked to clbp.the use of compensating custom-made foot orthoses has not been entirely explored as an effective therapy for clbp. customized foot orthoses alter the position of the foot during weight-bearing. the goal is to eliminate compensation of the foot due to structural deformity or misalignment and redistribute abnormal plantar pressures.custom-made foot orthoses may contribute to improving chronic low back pain. this question represents an important benefit for patients and for the public health system by reducing expensive treatments, such as surgery or long periods of rehabilitation

Eligibility criteria:
inclusion criteria: * males and females between 18 and 65 years old * presence of clbp * foot posture index pronated in one or both feet (henceforth, fpi) ≥ +6 exclusion criteria: * serious illness * current participation in another research study * pregnancy * previous back or foot surgery * current treatment of foot pathology or back, and leg length discrepancy \> 5 mm

Keywords: low back pain custom-made foot orthoses foot pronation posture
an observational study of mabthera/rituxan (rituximab) in patients with active rheumatoid arthritis who have an inadequate response to anti-tnf therapy (repeat)

Conditions: Rheumatoid Arthritis

Summary: this observational study will assess the efficacy and safety of mabthera/rituxan (rituximab) in patients with active rheumatoid arthritis who have had an inadequate response or are intolerant to anti-tnf therapy. data will be collected from patients initiated on mabthera/rituxan therapy according to standard of care in routine clinical practice. for each patient data will be collected for 92 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * active rheumatoid arthritis * inadequate response to anti-tnf * eligible for mabthera/rituxan therapy according to physician's decision exclusion criteria: * according to summary of product characteristics
pmcf study for peripheral arteries above the knee (atk)

Conditions: Peripheral Arterial Disease; Femoropopliteal Stenosis; Angiopathy, Peripheral

Summary: the rationale of this study is to confirm and support the clinical safety and performance of the products in a real-word population of 350 patients who underwent an endovascular intervention within standard-of-care (soc) of the ilio-femoropopliteal artery, using at least 1 of the products (named above) from cordis us corp.


Eligibility criteria:
inclusion criteria: 1. patient is \>18 years old at conduction of the procedure. 2. patient who underwent endovascular procedure of the ilio-femoropopliteal vessel with at least one of the following the s.m.a.r.t. flex stent iliac and/or s.m.a.r.t. flex sfa/pp and/or s.m.a.r.t. control nitinol stent and/or s.m.a.r.t. nitinol stent and/or palmaz blue .018 peripheral stent on slalom and/or palmaz genesis .035 peripheral stent on opta pro and/or saber otw pta catheter and/or saberx pta dilatation catheter and/or powerflex pro pta catheter as described in the ifu of the devices. 3. target lesion is located in the ilio-femoropopliteal vessels. exclusion criteria: 1. anatomy or size of vessels that did not allow appropriate usage of the devices, following ifu of the devices. 2. known contraindication and/or allergy to (a component of) the device as described in the ifu of the devices. 3. women who were pregnant or lactating at the time of the procedure. 4. life expectancy of less than 12 months at the time of procedure. 5. any patient who was hemodynamically unstable at onset of procedure.
a study of d4064a administered to patients with recurrent or persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer

Summary: this is a phase i, multicenter, open-label, dose-escalation study of single-agent d4064a administered by iv infusion to patients with recurrent or persistent epithelial ovarian cancer (eoc), primary peritoneal cancer (ppc), and fallopian tube cancer (ftc) who have previously received a platinum-containing regimen. the study will enroll up to 56 patients at up to six investigative sites in the united states.


Eligibility criteria:
inclusion criteria: * ecog performance status of 0 or 1 * advanced, histologically documented epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed during or within 12 months of treatment with a platinum-containing chemotherapy regimen, and for which no standard therapy exists * history of receiving five or fewer prior chemotherapy-containing regimens for eoc, ppc, or ftc (including primary therapy) exclusion criteria: * prior treatment with chemotherapy or experimental anti-cancer agents within 4 weeks prior to day 1 * prior treatment with oregovomab (ovarex(r)) or abagovomab * history or clinical evidence of central nervous system or brain metastases * grade ≥ 2 peripheral neuropathy * history of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies * history of clinically symptomatic liver disease, including viral or other hepatitis, history of or current alcoholism, or cirrhosis * untreated or persistent/recurrent malignancy (other than eoc, ppc, or ftc)

Keywords: eoc ppc ftc
introduction of dispersible 3hp formulations for tb preventive treatment in children: a multi-country evaluation

Conditions: TB - Tuberculosis; Household Contact; HIV; Children, Only

Summary: the who has recommended tb preventive therapy (tpt) for children living with hiv (clhiv) and household contacts of people living with tb, however, the scale-up and implementation of tpt has been sub-optimal globally particularly in children. a safe and effective short-course tpt regimen, 3hp (rifapentine and isoniazid given once weekly for three months), is available but there is a lack of child-friendly formulations resulting in increased pill burden and there is a need to improve acceptability and adherence among children. the introduction of a dispersible rifapentine formulation has potential to improve uptake, treatment adherence and completion. overall goal is to generate critical knowledge to improve delivery of tpt and, more specifically, of dispersible 3hp, in children in routine programs. this evaluation will create an important understanding of tpt uptake and completion among children and assess the impact of the introduction of a dispersible 3hp formulation. these results will provide actionable information for improving service delivery and the scale-up of tpt in the respective countries.


Eligibility criteria:
clinic record review inclusion criteria: * medical records of children \<12 years who are either clhiv or who are household contacts of people with pulmonary tb and who are initiated on tpt exclusion criteria: * records will be excluded for children who are contacts of a drug-resistant, have presumptive tb disease or are currently on tb treatment qualitative study inclusion criteria: * adult caregiver (\>18 years) of a child \<12 years of age who is eligible for tpt * healthcare worker from one of the clinics in which the study will be conducted who sees outpatient pediatric consultations including tb-exposed children * policy maker or program manager who manages or is involved in pmtct, tb and/or pediatric programming exclusion criteria: * any adult caregivers, healthcare workers, policy makers or program managers who are unable or unwilling to provide informed consent for both the interview and audio-recording.
adjuvant gemcitabine versus gemcitabine with chemoradiation in pancreatic adenocarcinoma with r1 resection and/or positive lymph nodes

Conditions: Pancreatic Neoplasms

Summary: adjuvant gemcitabine versus gemcitabine with chemoradiation in pancreatic adenocarcinoma with r1 resection and/or positive lymph nodes after curative resection.

adjuvant gemcitabine versus gemcitabine with ts-1 based chemoradiation in pancreatic adenocarcinoma with r1 resection and/or positive lymph nodes after curative resection: a randomized phase ii study.

Eligibility criteria:
inclusion criteria: * histologically confirmed resected ductal pancreatic adenocarcinoma with r1 resection and/or positive lymph nodes. * subject should start treatment no later than 10 weeks postsurgery. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * acceptable hematology parameters: * absolute neutrophil count ≥1500 cell/mm3 * platelet count ≥100,000/mm3 * hemoglobin (hgb) ≥8.0 g/dl * acceptable blood chemistry levels: * aspartate aminotransferase (ast) and alanine transaminase (alt) ≤2.5 × upper limit of normal range (uln) * total bilirubin ≤ 2.5 x upper limit of normal (uln) * serum creatinine within upper limits of normal. * cancer antigen (ca)19-9 ≤ 2.5 x upper limit of normal (uln) assessed within 14 days of randomization. * no disease recurrence or metastases detected on ct/mri assessed within 30 days of randomization. * signed informed consent. exclusion criteria: * r2 resection or presence of metastatic disease. * prior neo-adjuvant treatment or radiation therapy for pancreatic adenocarcinoma. * any other malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, bladder, or nonmelanomatous skin cancer. * active, uncontrolled infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate treatment. * severe, active co-morbidity, defined as follows: * unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months * transmural myocardial infarction within the 6 months of study registration * uncontrolled hypertension, diabetes or arrhythmia. * chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization. * not able to take medicine orally.

Keywords: adjuvant pancreatic cancer r1 resection positive lymph nodes
nurse delivered cell phone adherence intervention (pick it up)

Conditions: Medication Adherence

Summary: persistent adherence to antiretroviral therapy is necessary for the successful treatment of hiv infection. the proposed research will test a theory-based behavioral intervention that includes objectively monitoring hiv treatment adherence with corrective feedback delivered by cell phone. the study will also test the independent effects of an automated text message reminder system for sustaining adherence improvements. the intervention under study has utility for people living with hiv/aids in resource limited rural and urban settings.

this study is testing a theory-based hiv treatment adherence intervention delivered by cell phone to patients in urban and rural areas. adherence to antiretroviral (art) medications is necessary to achieve hiv suppression and non-adherence can lead to treatment resistant genetic variants of hiv. people living with hiv/aids often experience difficulty sustaining high-levels of treatment adherence. most factors that interfere with adherence are unanticipated and occur between clinical visits, including depression, side effects, substance use, and lapses in pharmacy refill. we will conduct a randomized clinical trial to test a cell phone-delivered theory-based medication adherence counseling intervention. the intervention is grounded in self-regulation model and utilizes unannounced pill counts to monitor adherence and guide corrective feedback within the counseling context. using pill count adherence information for counseling allows providers to detect and correct patient non-adherence within a time frame that can head off viral resistance. an experimental factorial design will test the effects of counseling and a text message reminder system as well the interaction of counseling and text message components with 600 men and women receiving hiv treatment. following screening, informed consent and baseline assessments participants will be randomized to one of four intervention conditions:(a) self-regulation counseling + regimen tailored text message reminders; (b) self-regulation counseling only; (c) control counseling + regimen tailored text reminders; or (d) control counseling only. the study will therefore use a 2 (self-regulation counseling) x 2 (text message reminders) full factorial deign with participants followed for 9 months post-intervention. the primary endpoints are medication adherence assessed by unannounced pill counts and hiv rna (viral load). this newly developed intervention strategy is grounded in self-regulation theory and is designed for use in clinical settings with limited resources.

Eligibility criteria:
inclusion criteria: * age 18 or older * currently taking hiv treatment medication with non-adherence exclusion criteria: * under age 18 * not hiv positive * not taking hiv treatment medications * adherent to hiv medications

Keywords: hiv aids medication adherence
preoperative non-steroidal anti-inflammatory drugs(nsaid) to colorectal cancer patients

Conditions: Colorectal Cancer

Summary: the study is designed to evaluate effects of nsaids on immune activity inside and close to tumor tissue in patients with colorectal cancer.

study and control patients are randomized to receive preoperative treatment with indomethacin or celecoxib compared to sham treatment.tumor biopsies are taken at operation and used for analyses of tumor immunity and gene expression.

Eligibility criteria:
inclusion criteria: * colon carcinoma scheduled for curative operation exclusion criteria: * diabetes, steroid medication, liver and kidney impairment

Keywords: mhc ctls colon carcinoma nsaid survival
effects of virtual reality based games in rehabilitation of parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to investigate the effects of virtual reality based games on upper extremities, trunk and cognitive functions in patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease * 50 years old and over * stage 1.5-3 according to the modified hoehn-yahr staging scale * mini mental test score of 24 and above exclusion criteria: * additional neurological disease or symptom other than parkinson's disease * orthopedic disorder that will prevent them from doing exercises * severe mental disorders

Keywords: parkinson disease physiotherapy exergames